BRPI0519705A2 - composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo - Google Patents

composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo

Info

Publication number
BRPI0519705A2
BRPI0519705A2 BRPI0519705-8A BRPI0519705A BRPI0519705A2 BR PI0519705 A2 BRPI0519705 A2 BR PI0519705A2 BR PI0519705 A BRPI0519705 A BR PI0519705A BR PI0519705 A2 BRPI0519705 A2 BR PI0519705A2
Authority
BR
Brazil
Prior art keywords
compositions
fusion proteins
individual
immune response
stimulating
Prior art date
Application number
BRPI0519705-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas J Powell
Valerian Nakkar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of BRPI0519705A2 publication Critical patent/BRPI0519705A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0519705-8A 2004-12-21 2005-12-21 composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo BRPI0519705A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30
PCT/US2005/046662 WO2006069262A2 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0519705A2 true BRPI0519705A2 (pt) 2009-03-10

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519705-8A BRPI0519705A2 (pt) 2004-12-21 2005-12-21 composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo

Country Status (9)

Country Link
EP (1) EP1831259A2 (es)
JP (1) JP2008524261A (es)
AU (2) AU2005319141B8 (es)
BR (1) BRPI0519705A2 (es)
CA (1) CA2593746A1 (es)
MX (1) MX2007007586A (es)
NZ (1) NZ556004A (es)
SG (1) SG160424A1 (es)
WO (1) WO2006069262A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US20100068224A1 (en) * 2006-04-24 2010-03-18 Roberto Crea Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
CN104080475A (zh) 2008-04-18 2014-10-01 法克斯因内特公司 鞭毛蛋白的缺失突变体以及使用方法
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
MX341775B (es) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vectores para vacunas y metodos para potenciar respuestas inmunes.
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US9889189B2 (en) 2012-11-05 2018-02-13 Georgia State University Research Foundation Universal influenza vaccine based on heterologous multiple M2E proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
CA3226951A1 (en) * 2021-09-02 2023-03-09 Grant MCLACHLAN Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688606B (zh) * 2002-08-12 2013-12-25 昆士兰医学研究所理事会 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine

Also Published As

Publication number Publication date
MX2007007586A (es) 2007-12-10
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29
JP2008524261A (ja) 2008-07-10
EP1831259A2 (en) 2007-09-12
SG160424A1 (en) 2010-04-29
AU2005319141B2 (en) 2010-02-18
WO2006069262A3 (en) 2007-02-01
WO2006069262A2 (en) 2006-06-29
AU2010200048A1 (en) 2010-01-28
AU2005319141B8 (en) 2010-03-18
CA2593746A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
BRPI0606479A (pt) composições; proteìnas de fusão; polipepitìdeos; e métodos para estimular uma resposta imune em um indivìduo
DK1939281T3 (da) Immortaliserede andecellelinjer til virusproduktion
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
NO20063026L (no) Antistoffer
BR0212363A (pt) Expressão hìbrida e em tandem de proteìnas de neisseria
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
AR070690A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos)
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
DK1879612T3 (da) Anvendelse af native peptider og deres optimerede derivater til vaccination
EA201100071A1 (ru) Новые композиции и способы
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.